Literature DB >> 990157

Acute effect of intravenous labetalol in the treatment of systemic arterial hypertension.

J O Ronne-Rasmussen, G S Andersen, N B Jensen, E Andersson.   

Abstract

1 The acute anti-hypertensive effect of intravenously administered labetalol, a combined alpha- and beta-adrenoreceptor antagonist, has been assessed in a pilot study involving 17 hypertensive patients. 2 In 11 patients with mild to moderately severe hypertension, there was a decrease in mean arterial pressure (24 mmHg) after a single intravenous dose of 50 mg labetalol. The peak response occurred approximately 4 min after administration of the drug. 3 In six patients with severe hypertension, there was a reduction in mean arterial pressure of 19 mmHg, but this was achieved after a further 50-mg dose administered 30 min after the initial injection. 4 In neither group was there any clinically significant decrease in heart rate, and drug-related side-effects were insignificant. 5 Labetalol reduced the blood pressure when administered intravenously and thus merits further investigation as a treatment for acute hypertensive crises.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 990157

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

Review 1.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

Review 2.  Labetalol: a review of its pharmacology and therapeutic use in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

Review 3.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

4.  Acute and long-term effects of labetalol on systemic and pulmonary haemodynamics in hypertensive patients.

Authors:  T L Svendsen; S Rasmussen; O J Hartling; P E Nielsen; J Trap-Jensen
Journal:  Eur J Clin Pharmacol       Date:  1980-01       Impact factor: 2.953

5.  The use of labetalol in anaesthesia.

Authors:  D B Scott
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 6.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 7.  Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.

Authors:  P Lund-Johansen
Journal:  Drugs       Date:  1984       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.